Recent Updates
Recently added Catalysts
OM Negative Sentiment Score: 20/100

Outset Medical, Inc. (OM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: Outset Medical, Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC for potential claims related to recent financial results. The company reported a substantial miss in its Q2 2024 estimates and downgraded its outlook for the entire year. Following these announcements, shares of Outset plummeted by 68.53%, prompting concerns among investors regarding potential wrongdoing. The firm encourages affected investors to participate in the investigation and share any pertinent information.

Market Sentiment Analysis

CONCERNS & RISKS

  • Outset Medical missed consensus estimates significantly for Q2 2024.
  • The company lowered its full year 2024 outlook, indicating financial distress.
  • Shares fell by 68.53% following the announcement, signaling loss of investor confidence.

Full Press Release Details

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. (“Outset” or “the Company”) (NASDAQ: OM). Investors who purchased Outset securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/OM.
Investigation Details
On August 7, 2024, Outset released its second quarter 2024 financial results. The Company missed consensus estimates by a considerable margin and lowered its full year 2024 outlook. According to the Company, the “changes [it] needs to make are entirely in [its] control” and will involve “shifts and adjustments” to its sales team and processes. Based on this news, shares of Outset fell by 68.53% on August 8, 2024.
If you are aware of any facts relating to this investigation or purchased Outset securities, you can assist this investigation by visiting the firm’s site: bgandg.com/OM. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What did Outset Medical announce on August 7, 2024?

Outset Medical announced its second quarter 2024 financial results, missing estimates.

Why did Outset's shares drop significantly?

Shares fell by 68.53% following their lowered full-year outlook and poor results.

How can investors assist the investigation?

Investors can assist by visiting bgandg.com/OM for more information.

Is there any cost to participate in the investigation?

No, the firm works on a contingency fee basis, charging only upon success.

What services does Bronstein, Gewirtz & Grossman provide?

The firm represents investors in securities fraud class actions and derivative suits.

Last updated: Aug 16, 2024